MiMedx is in trouble, again; Pfizer's Avastin biosimilar wins FDA approval
→ The controversial MiMedx has dug itself a deeper hole. Senior officials at the wound care company, which has long been criticized for its business …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.